Résumé
OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. DESIGN: Observational study. SETTING: Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. PARTICIPANTS: Twenty-four raters (physicians and nurses) familiar with drug trials and expert in the care of patients with Alzheimer's disease. METHODS: Independent scoring of the CDR using four videotaped CDR interviews. OUTCOME MEASURE: Interrater reliability, as tested by the Kappa statistic RESULTS: The overall interrater reliability was 0.62. Within the CDR domains, the global kappas ranged from 0.33 ± 0.06 to 0.88 ± 0.06. CONCLUSIONS: The data support moderate to high overall interrater reliability but show important difficulties in the reliable assessment of early dementia.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 558-559 |
| Nombre de pages | 2 |
| Journal | Journal of the American Geriatrics Society |
| Volume | 48 |
| Numéro de publication | 5 |
| DOI | |
| Statut de publication | Published - mai 2000 |
ASJC Scopus Subject Areas
- Geriatrics and Gerontology
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.